Navigation Links
Antibody in Biological Technology

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

... Inc., a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today ... and recurrence." OMP-21M18 is a monoclonal antibody that blocks DLL4 signaling to reduce tumor growth ... About OMP-21M18 OMP-21M18 is a monoclonal antibody optimized to block a key signaling pathway in ...

Micromet Closes $80.5 Million Public Offering of Common Stock

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... the European Medicines Agency (EMEA) for BiTE antibody blinatumomab (MT103) for acute lymphoblastic leukemia (ALL). Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out ... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ...

Micromet Announces Pricing of Public Offering of Common Stock

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

Micromet Announces Public Offering of Common Stock

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009

... PDL is focused on maximizing the value of its antibody humanization patents and related assets. The ... royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

OMT announces a breakthrough in the development of a novel human antibody platform

... the development of OMT's novel human monoclonal antibody platform. "Creating a knockout rat was the ... of the paper. "Inactivation of endogenous rat antibody expression is essential for human antibody expression in genetically engineered animals. To ...

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

... they have entered into a licensing agreement for antibody therapeutic rights under Peregrine's preclinical anti-VEGF (Vascular Endothelial Growth Factor) antibody program. Under the terms of the agreement, ... property portfolio, including the fully human antibody r84, which was discovered by Affitech and jointly ...

Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies

... all of which have successfully induced antibody responses in mice. Novavax scientists have now ... a broad set of immune responses including antibody and cell mediated immune responses to prevent ... that the RSV-F vaccine induced neutralizing antibody responses at all doses evaluated. The highest ...

Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies

... approach to targeting tumor-associated proteins. antibody targeting of tumor-associated proteins has ... as we continue to grow our therapeutic antibody portfolio." "CII has developed several ... for cancer." Morphotek will apply its antibody discovery technologies, including its proprietary ...

BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA

... development and commercialization of their antibody therapies with enhanced antibody-dependent ... Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT((R)) Technology ...

MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus

... MGAWN1 MGAWN1 is a humanized monoclonal antibody that specifically recognizes the envelope (E) ... set of capabilities in monoclonal antibody product development. The company's product ... lead program, teplizumab, is an anti-CD3 antibody being developed for the treatment of autoimmune ...

Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease

... "Morphotek is an industry leader in antibody discovery and development," said Sanj K. Patel, ... collaboration." "We have a rich pipeline of antibody products such as MORAb-003, or farletuzumab, for ... may enhance the manufacturing process for our antibody products as a means to fulfill Eisai's hhc ...

Micromet Added to Russell 3000 Index

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

Paulo F. Costa Joins MacroGenics Board of Directors

... that MacroGenics has one of the best monoclonal antibody therapeutics programs, including a rich pipeline ... set of capabilities in monoclonal antibody product development. The company's product ... lead program, teplizumab, is an anti-CD3 antibody being developed for the treatment of autoimmune ...

Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM)

... SIAL ) today announced the release of over 2,300 antibody additions to its Prestige Antibodies(R) powered ... Proteome Resource's goal to develop at least one antibody to all 22,000 non-redundant human proteins by ... Sigma-Aldrich has significantly expanded our antibody offerings, the latest step in our long-term plan ...

New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease

... dose of Prevenar 13 or Prevenar at 12 months. antibody response was measured at month 13. Both of the ... and 11 months of age. Assessment of functional antibody levels (serotype specific opsonphagocytic assay) ... were either comparable to or greater than the IgG antibody concentrations achieved in infants after a 3-dose ...

PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million

... PDL is focused on maximizing the value of its antibody humanization patents and related assets. The ... royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late ...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

... II trial of its lead anti-phosphatidylserine antibody bavituximab in combination with docetaxel in ... 7.4 months. Bavituximab is a monoclonal antibody with a unique anti-cancer mechanism that works by ... treatments. Bavituximab is a monoclonal antibody that binds specifically to these phospholipids ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... results reported for cetuximab, an EGFR-targeting antibody marketed as Erbitux(R), but that this efficacy ... assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation ... Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple ...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... clinical trial investigating its anti-EpCAM human antibody adecatumumab (MT201) in combination with the ... n=19 evaluable for efficacy). Adecatumumab is an antibody that targets EpCAM, a tumor antigen known to be ... Her-2 and thus do not qualify for Her-2-targeting antibody therapy." (1) Sebastian, M. et al. (2009). ...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

... treated with anti-CD19/-CD3 bispecific BiTE(R) antibody blinatumomab. 14th Congress of EHA (2009), ... and antitumor activity of 3-weekly anti-EpCAM antibody adecatumumab (MT201) in combination with ... and autoimmune diseases. The Company's novel antibody technology is based on its proprietary ...

Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement

... a subset of antibodies in Morphotek's therapeutic antibody pipeline. The agreement will reserve capacity for ... scale expression and purification of commercial antibody products. They have demonstrated their ability to ... production, quality goals and timelines for our antibody programs." "Lonza is excited to participate ...

PDL BioPharma Announces First Quarter 2009 Financial Results

... PDL is focused on maximizing the value of our antibody humanization patents and related assets. PDL receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late ...

Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009

... and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies ... development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase ...

Medarex Announces 2009 First Quarter Financial Results

... MEDI-546, a fully human anti-type 1 interferon antibody for the treatment of scleroderma, a chronic ... inflammatory diseases and is the second human antibody generated using Medarex's UltiMAb(R) technology ... & Co, Inc., for the MDX-066 and MDX-1388 antibody combination treatment for C. difficile ...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... by HGS, generating and developing all monoclonal antibody candidates using proprietary Morphotek ... in the development and commercialization of each antibody candidate. CONFERENCE CALL HGS ... treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP ...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

... and prostate cancer, as well as for an anti-PD-1 antibody for cancer treatment, have been selected to be ... "Phase 2 trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly known as MDX-010) with a ... commercialize a broad range of fully human antibody product candidates for itself and its partners. ...

PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research

... to respond to natural infection by producing antibody due to immunologic memory.) The three dose ... SparVax(TM) was safe, well-tolerated and produced antibody responses comparable to the currently licensed ... Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax ...

Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110

... in Denver, Colorado, showing that its BiTE(R) antibody MT110 can eliminate cancer stem cells (1). Cancer ... The data presented at AACR show that the BiTE antibody MT110 can direct T cells to eliminate ... a study of MT110 in mice showed that the BiTE antibody eliminated even large numbers of implanted cancer ...

AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies

... of the modified anti-CD20 human-mouse chimeric antibody exposed unexpected adverse activity that may not ... increase the binding strength between the antibody and the target antigen, as determined repeatedly ... and " Oxidative Modification Of An Anti-CD20 antibody Imparts Autophilic Binding Kinetics ", (AACR# ...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

... 1 and 2; AMG 479, a fully human monoclonal antibody antagonist of the type 1 insulin-like growth ... (IGF-1R) and AMG 102, a fully human monoclonal antibody antagonist of HGF, the ligand for the c-Met ... Overview: Evaluated the effect of a novel antibody to the IGF-1R (AMG 479) on cell ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

... the potent anti-tumor activity of a BiTE antibody binding to carcinoembryonic antigen (CEA) and to ... as target antigen for development of a new BiTE antibody program because CEA is widely expressed on the ... on the surface of cancer cells, thereby limiting antibody efficacy. The new study shows that novel BiTE ...

BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis

... development and commercialization of their antibody therapies with enhanced antibody-dependent ... Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT(R) Technology involves ...

Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009

... and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies ... development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase ...

Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology

... by HGS, generating and developing all monoclonal antibody candidates using proprietary Morphotek ... proof of concept studies. With respect to each antibody candidate, HGS and Morphotek will have the right ... with Human Genome Sciences to apply our antibody technology to a range of novel targets that stem ...

Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics

... of Sir Walter Bodmer and Bernard Fox to its BiTE antibody advisory panel. Other members of the company's ... and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies ...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

... "Efficacy of MDX-1110, an anti-Fucosyl-GM1 antibody in a SCLC tumor model" (Abstract #838), B. Chen - ... "Efficacy and Toxicity of anti-mesothelin antibody drug conjugate" (Abstract #3235), C. Rao - Poster ... commercialize a broad range of fully human antibody product candidates for itself and its partners. ...
Other Contents
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report ... markets for Hand Geometry in US$ Thousands. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates ...
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
(Date:5/2/2015)... Beach, FL (PRWEB) May 02, 2015 ... has selected The Delray Recovery Center as one of ... Center is known in the addiction treatment field for ... staff members to innovate and to continue their educational ... a positive workplace environment, never forgetting their purpose – ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare ... its new healthcare insurance to individuals and small businesses ... System is the nation’s first health insurance system built ... Personal Health Insurance was ZoomCare’s first such filing including ... to review and regulation by the Oregon Insurance Division. ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious ... its flagship nutritional supplement, Liquid BioCell™ Life, and the ... new logo, new packaging, new products, and new messaging. ... identify and promote programs that serve as examples of ... Jusuru International for their outstanding accomplishments and contributions to ...
(Date:5/1/2015)... 2015 Hope For The Warriors® thanks ... For The Warriors® and military families. All American Ford ... For The Warriors®, a national nonprofit dedicated to restoring ... restoring hope for our service members and our military ... Ford collected and matched small autograph fee from fans ...
(Date:5/1/2015)... Colorado (PRWEB) May 01, 2015 As ... States approaches its 18-month anniversary, many people in the ... been achieved. , According the latest annual report by ... expanded 74 percent in 2014, and reached nearly $3 ... America’s decades-long love affair with cannabis, combined with the ...
Breaking Medicine News(10 mins):Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 3
Other TagsOther Tags